Ideaya Biosciences Inc (IDYA)vsRoyalty Pharma Plc (RPRX)
IDYA
Ideaya Biosciences Inc
$28.29
-3.18%
HEALTHCARE · Cap: $2.74B
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 983% more annual revenue ($2.44B vs $225.27M). RPRX leads profitability with a 33.9% profit margin vs -62.2%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
IDYA
Avoid35
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.0%
Fair Value
$145.17
Current Price
$28.29
$116.88 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
ROE of -14.9% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IDYA
The strongest argument for IDYA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 55.4% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : IDYA
The primary concerns for IDYA are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
IDYA profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
IDYA is growing revenue faster at 55.4% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 35/100), backed by strong 33.9% margins and 11.0% revenue growth. IDYA offers better value entry with a 78.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ideaya Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?